Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence | Zendy

Tanner M Johnson | Zendy; Kyle C. Molina | Zendy; Amanda Howard | Zendy; Kerry Schwarz | Zendy; Lorna Allen | Zendy; Misha Huang | Zendy; Valida Bajrovic | Zendy; Matthew A. Miller | Zendy

Open Access

Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence

Author(s) -

Tanner M Johnson,

Kyle C. Molina,

Amanda Howard,

Kerry Schwarz,

Lorna Allen,

Misha Huang,

Valida Bajrovic,

Matthew A. Miller

Publication year - 2021

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciab674

Subject(s) - medicine , odds ratio , incidence (geometry) , confidence interval , clostridioides , retrospective cohort study , optics , physics

Bezlotoxumab (BEZ) is a monoclonal antibody used to prevent recurrent Clostridioides difficile infection (rCDI). This study investigates BEZ effectiveness in relation to rCDI and patient-specific risk factors in a real-world setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research